Learn About Medicare GLP-1 Bridge Programs

What Are Medicare GLP-1 Bridge Programs?

A GLP-1 bridge program is a way for people with Medicare coverage to obtain glucagon-like peptide-1 (GLP-1) medications while waiting for their Medicare coverage to take effect or to change. GLP-1 medications are injectable drugs originally developed to treat type 2 diabetes. In recent years, they have gained attention for their potential to help people lose weight. Brand names include Ozempic, Mounjaro, and Wegovy, though many other versions exist.

These bridge programs are offered by pharmaceutical manufacturers—the companies that make the drugs—not by Medicare itself. The programs work by providing medications at reduced cost or free for a limited time period. The idea is to "bridge" the gap when someone cannot yet receive their Medicare-covered medication or when there are delays in accessing it through normal channels.

It is important to understand that bridge programs are separate from Medicare benefits. They are manufacturer-run programs with their own rules, timeframes, and requirements. Some people use these programs while waiting for their Medicare Part D (prescription drug coverage) to cover the medication. Others use them during coverage gaps or transitions between insurance plans.

According to recent data, approximately 3.7 million Medicare beneficiaries took GLP-1 medications in 2023. However, access remains uneven across different regions and pharmacy networks. Bridge programs emerged partly because of high out-of-pocket costs and coverage limitations that many people face with these medications.

Practical Takeaway: Bridge programs are temporary medication access programs run by drug makers, not government benefits. They are different from Medicare coverage and have their own separate rules and time limits.

How GLP-1 Bridge Programs Work

Bridge programs operate on a straightforward principle: a pharmaceutical company provides medication directly to patients or through partner pharmacies for reduced or no cost during a defined period. The program typically lasts between one and three months, though some extend longer. Each manufacturer sets its own program rules.

To understand the mechanics, consider this example: A person with Medicare is prescribed Ozempic by their doctor. Their Medicare Part D plan has a prior authorization requirement, meaning the insurance company wants additional information before approving coverage. While waiting for that approval—which might take two to four weeks—the patient experiences delays getting the medication. The manufacturer's bridge program can provide the medication during this waiting period at no cost or low cost.

Here is how the process typically unfolds:

• A doctor writes a prescription for a GLP-1 medication
• The patient or healthcare provider contacts the manufacturer's bridge program
• Program staff review the patient's information to confirm they have Medicare and meet basic program requirements
• If accepted, the manufacturer sends the medication to a pharmacy or directly to the patient
• The patient receives the medication during the bridge period
• Once regular Medicare coverage begins, the patient transitions to standard coverage

Different manufacturers structure their programs differently. Some require the patient's doctor to initiate contact. Others allow patients to enroll directly. Some programs automatically transition people to coupons or discount programs when the bridge period ends. Understanding your specific manufacturer's program structure is important before enrolling.

A critical detail: bridge programs do not change Medicare coverage decisions. If Medicare Part D initially denies coverage for a medication, receiving it through a bridge program does not change that denial. Bridge programs are meant to be temporary solutions, not permanent alternatives to insurance coverage.

Practical Takeaway: Bridge programs provide medication for a set time period while you work through insurance coverage issues. Learn your specific manufacturer's program rules before beginning, as each program differs.

Medicare Coverage Rules for GLP-1 Medications

Understanding what Medicare covers and does not cover is essential when considering bridge programs. Medicare's approach to GLP-1 medications involves coverage through Part B and Part D, but with important limitations.

Medicare Part B covers some GLP-1 medications when used specifically for diabetes treatment in certain clinical settings, typically administered in a doctor's office or hospital outpatient department. Part D, the prescription drug coverage part of Medicare, covers GLP-1 medications dispensed at retail pharmacies for diabetes treatment. However, Part D coverage varies by specific plan and formulary.

A major coverage restriction affects weight-loss uses. As of 2024, Medicare generally does not cover GLP-1 medications for weight loss or weight management, even though FDA-approved versions like Wegovy exist for this purpose. This means if someone wants to use a GLP-1 medication for weight loss under Medicare, they would need to pay out-of-pocket. This is where bridge programs sometimes enter the picture—they may allow people to access these medications during the bridge period even for uses Medicare would not typically cover.

Medicare Part D also imposes restrictions such as:

• Step therapy requirements, meaning a patient must try other medications first
• Prior authorization, requiring doctor approval before coverage begins
• Quantity limits, restricting how much medication can be obtained per time period
• Formulary restrictions, meaning some GLP-1 versions are covered while others are not

These restrictions frequently create delays. A 2023 survey found that approximately 42% of Medicare beneficiaries seeking GLP-1 medications experienced coverage delays or denials. Bridge programs fill this gap during these waiting periods.

It is also worth noting that Medicare's coverage landscape is evolving. Recent policy discussions have explored expanding coverage for weight-loss uses, but as of now, this remains limited. Checking your specific Medicare Part D plan's formulary on Medicare.gov provides the most current information about what your plan covers.

Practical Takeaway: Medicare covers GLP-1 medications for diabetes through Part D and Part B, but generally not for weight loss. Coverage restrictions often create delays that bridge programs address.

When Bridge Programs May Be Useful

Bridge programs serve specific situations where someone has Medicare coverage but faces barriers to receiving their medication. Recognizing when a bridge program might address your situation helps you determine whether exploring one makes sense.

The most common scenario involves prior authorization delays. A doctor prescribes a GLP-1 medication, but the Medicare Part D plan requires prior authorization—written permission from the insurance company confirming medical necessity. This process typically takes five to ten business days but sometimes extends longer if the insurance company requests additional information from the doctor. During this waiting period, a bridge program can provide the medication.

Coverage gaps create another common scenario. Someone covered under Medicare for part of the year might lose coverage temporarily when switching plans during Open Enrollment (October 15 through December 7 annually). A bridge program could provide medication during this transition.

Quantity limit restrictions also lead to bridge program use. If a Medicare plan limits coverage to one injection per month but a doctor prescribes weekly injections, there may be gaps between what insurance covers and what the patient receives. Bridge programs can fill these gaps.

A realistic example: Maria, age 68, has Medicare Part D. Her doctor prescribes Ozempic for type 2 diabetes. Her plan requires prior authorization, which the doctor's office submits on a Monday. The insurance company takes seven business days to review, issuing approval the following Tuesday. During those seven days, if Maria needed immediate access to her first dose, the manufacturer's bridge program could provide it. Once insurance approval arrives, she transitions to using her Part D coverage.

However, bridge programs may not help in certain situations. If someone is not yet eligible for Medicare, bridge programs typically do not apply. If someone has private insurance through an employer (not Medicare), they would explore the private insurance company's options instead. If someone has no insurance at all, manufacturer assistance programs exist but operate differently than bridge programs.

Practical Takeaway: Bridge programs work best for temporary coverage gaps during prior authorization waits, plan transitions, or quantity limit restrictions. They address specific timing problems rather than serving as long-term solutions.

Information Resources and Next Steps

Finding information about specific GLP-1 bridge programs requires going directly to manufacturer websites or consulting with your healthcare provider. Each pharmaceutical company maintains its own program with different enrollment processes and requirements.

The major GLP-1 medication manufacturers include Novo Nordisk